Trial
NCT05071183
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Turning Point Therapeutics, Inc.
Collaborators
—
Condition
KRAS Mutation-Related Tumors
Intervention
TPX-0005
Why stopped
Inability to achieve and optimize a dose that could provide a positive benefit risk profile
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-02